RUNX1: an emerging therapeutic target for cardiovascular disease.

Cardiovascular Research
Alexandra RiddellTamara P Martin

Abstract

Runt-related transcription factor-1 (RUNX1), also known as acute myeloid leukaemia 1 protein (AML1), is a member of the core-binding factor family of transcription factors which modulate cell proliferation, differentiation, and survival in multiple systems. It is a master-regulator transcription factor, which has been implicated in diverse signalling pathways and cellular mechanisms during normal development and disease. RUNX1 is best characterized for its indispensable role for definitive haematopoiesis and its involvement in haematological malignancies. However, more recently RUNX1 has been identified as a key regulator of adverse cardiac remodelling following myocardial infarction. This review discusses the role RUNX1 plays in the heart and highlights its therapeutic potential as a target to limit the progression of adverse cardiac remodelling and heart failure.

References

Dec 1, 1994·Molecular and Cellular Biology·X ZhuS J Burden
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·E OgawaY Ito
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·Q WangN A Speck
Mar 5, 1996·Proceedings of the National Academy of Sciences of the United States of America·M C GhoziY Groner
Apr 2, 1999·European Journal of Biochemistry·M Wolf-WatzT Härd
Aug 18, 2000·Cardiovascular Research·R MazhariA D McCulloch
Apr 18, 2002·European Journal of Heart Failure·Philipp StawowyKristof Graf
May 25, 2002·Molecular and Cellular Biology·Andrew N CarrEvangelia G Kranias
Dec 14, 2002·Science·Kenneth D PossMark T Keating
May 7, 2003·Blood Cells, Molecules & Diseases·Ewan R CameronJames C Neil
Aug 26, 2003·The American Journal of Pathology·Stefan GattenlöhnerAlexander Marx
Jan 31, 2004·The Journal of Biological Chemistry·Yuko YamaguchiHisamaru Hirai
May 25, 2004·Oncogene·Ditsa Levanon, Yoram Groner
May 3, 2005·Nature Reviews. Cancer·Karen BlythJames C Neil
May 24, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Hiroshi AshikagaElliot R McVeigh
Jul 19, 2005·Genes & Development·Xiaoxia WangSteven J Burden
Dec 6, 2005·Journal of the American College of Cardiology·Masakuni KidoPatricia A Thistlethwaite
Nov 18, 2006·Cardiovascular Research·Marcin Bujak, Nikolaos G Frangogiannis
Sep 6, 2007·The Journal of Clinical Investigation·Eva van Rooij, Eric N Olson
Nov 15, 2007·Physiological Genomics·Jose-Luis Gonzalez de AguilarJean-Philippe Loeffler
Aug 1, 2008·Nature·Matthias SelbachNikolaus Rajewsky
Aug 30, 2008·Proceedings of the National Academy of Sciences of the United States of America·Eva van RooijEric N Olson

❮ Previous
Next ❯

Citations

Nov 27, 2020·International Journal of Molecular Sciences·Glória ConceiçãoInês Falcão-Pires
Nov 17, 2020·Frontiers in Genetics·Sushmitha DudduPraphulla Chandra Shukla
Sep 7, 2020·Cellular Signalling·Dylan O'TooleTamara P Martin
May 19, 2021·Progress in Biophysics and Molecular Biology·Abimbola J AminuHalina Dobrzynski
Jun 17, 2021·British Journal of Pharmacology·Tamara P MartinChristopher M Loughrey
Aug 19, 2021·Pediatric Research·Melanie R F GroplerKathleen E Simpson

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
acetylation
RNA-seq

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.